Remdesivir is an antiviral. Its goal is to reduce the replication of the virus allowing patients to recover faster.

Leronlimab is a Monoclonal Antibody that also reduces viral load (not yet proven) but also calms the cytokine storm and restores the normal immune function of the body.

It remains to be seen which will reduce viral load more, but we are confident that Leronlimab will reduce fatality significantly (where as Remdesivir will not)